Table 2.

Descriptive statistics and internal consistency of the University of California at Los Angeles (UCLA) Scleroderma Clinical Trial Consortium GI Tract Instrument (UCLA SCTC GITI) 2.0, using the Canadian Scleroderma Research Group cohort (n = 113).

Scale	No. Items	Mean	SD	Median	Range of Scores in Our Patients		% with Floor Effect^*	% with Ceiling Effect^**	Cronbach’s Alpha Coefficient
Scale	No. Items	Mean	SD	Median	Min	Max	% with Floor Effect^*	% with Ceiling Effect^**	Cronbach’s Alpha Coefficient
Reflux	8	0.43	0.52	0.25	0	3	0.9	25.7	0.83
Distension/bloating	4	0.86	0.82	0.67	0	3	0.9	24.8	0.82
Diarrhea	2	0.33	0.57	0	0	2	3.5	67.3	0.80
Fecal soilage	1	0.35	0.68	0	0	3	2.7	73.5	0.00
Constipation	4	0.47	0.60	0.25	0	2.50	2.7	46.0	0.85
Emotional well-being	9	0.39	0.54	0.11	0	2.44	0.0	45.1	0.87
Social functioning	6	0.32	0.44	0.17	0	2.33	0.0	45.1	0.77
Total UCLA SCTC GITI score	30	0.45	0.43	0.33	0.00	1.86	0.9	9.7	0.83

↵* Since 0 represents the absence of the GI problem, the floor effect represents the percentage that scored the maximum possible score.
↵** Represents percentage that scored the minimum possible score, which represents the absence of a problem.